A view on noradrenergic, hypothalamic-pituitary-adrenal axis and extrahypothalamic corticotrophin-releasing factor function in anxiety and affective disorders: The reduced growth hormone response to clonidine

Psychopharmacology Bulletin

Volumn 33, Issue 2, 1997, Pages 193-204

  Coplan, Jeremy D ^a   Pine, Daniel S ^b   Papp, Laszlo A ^b   Gorman, Jack M ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Unit 24 ^*

Author keywords

Clonidine; Corticotrophin releasing factor; Growth hormone; Hypothalamic pituitary adrenal axis; Major depressive disorder; Noradrenaline; Panic disorder

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ALPRAZOLAM; CLONIDINE; CORTICOTROPIN RELEASING FACTOR; FLUOXETINE; GROWTH HORMONE; HYDROCORTISONE; SOMATOSTATIN; YOHIMBINE;

AFFECTIVE NEUROSIS; ANXIETY NEUROSIS; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; HORMONAL REGULATION; HORMONE RELEASE; HORMONE RESPONSE; HYPOPHYSIS ADRENAL SYSTEM; PANIC; PATHOGENESIS; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANXIETY; CLONIDINE; CORTICOTROPIN-RELEASING HORMONE; DEPRESSIVE DISORDER; GROWTH HORMONE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MOOD DISORDERS; PANIC DISORDER; PITUITARY-ADRENAL SYSTEM; RECEPTORS, ADRENERGIC, ALPHA-2; STRESS DISORDERS, POST-TRAUMATIC;

EID: 0030790457     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Abelson, JL; Glitz, D; Cameron, OG; Lee, MA; Bronzo, M; and Curtis, GC. Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch. Gen. Psychiatry 48:157-162, 1991.
2. Abelson, JL; Glitz, D; Cameron, OG; Lee, MA; Bronzo, M; and Curtis, GC. Endocrine, cardiovascular and behavioral responses to clonidine in patients with panic disorder. Biol. Psychiatry 32:18-25, 1992.
3. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: The Association, 1994.
4. Anand, A; Charney, DS; Delgado, PL; McDougle, CJ; Heninger, GR; and Price, LH. Neuroendocrine and behavioral responses to intravenous mCPP in depressed patients and healthy comparison subjects. Am. J. Psychiatry 151:(11):1626-1630, 1994.
5. Andrews, MW, and Rosenblum, LA. Relationship between foraging and affiliative social referencing in primates. In: Ecology and Behavior of Food-Enhanced Primate Group, 1988. pp. 247-252.
6. Andrews, MW, and Rosenblum, LA. Dominance and social competence in differentially reared Bonnet Macaques. Primatology Today, 1991. pp. 347-350.
7. Aulakh, CS; Hill, JL; and Murphy, DL. Attenuation of clonidine-induced growth hormone release following chronic glucocorticoid and 5-hydroxytryptamine uptake-inhibiting antidepressant treatments. Neuroendocrinology 59(1):35-41, 1994.
8. Baer, L. Behavior therapy: endogenous serotonin therapy? J. Clin. Psychiatry 57(Suppl. 6):33-35, 1996.
9. Baraban, FM, and Aghajanian, GK. Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoreceptor antagonist. Neuropharmacology (18):355-363, 1980.
10. Barlow, DH. Anxiety and its Disorders: The Nature and Treatment of Anxiety and Panic. The Guilford Press, New York, 1988.
11. Blier, P; de Montigny, C; and Chaput, Y. Modifications of the serotonin system by antidepressant treatments: Implications for the therapeutic response in major depression. J. Clin. Psychopharmacol. 7(Suppl. 6):24s-35s, 1987.
12. 2-adrenergic receptor sensitivity in panic disorder: I. GH Response to GHRH and clonidine stimulation in panic disorder. Psychoneuroendocrinology 20(1):1-9, 1995a.
13. 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder. Psychoneuroendocrinology 20(1):11-19, 1995b.
14. Butler, PD; Weiss, JM; Stout, JC; and Nemeroff, CB. Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. J. Neurosci. 10(1):176-183, 1990.
15. Cameron, OG; Smith, CB; Lee, MA; Hollingsworth, PJ; Hill, EM; and Curtis, GC. Adrenergic status in anxiety disorders: Platelet alpha-2-adrenergic receptor binding, blood pressure, pulse and plasma catecholamines in panic and generalized anxiety disorder patients and in normal subjects. Biol. Psychiatry 28:3-20, 1990.
16. Castro, RC; Vieira, JGH; Chacra, AR; Besser, GM; Grossman, AB; and Lengyel, AMJ. Pyridostygmine enhances but does not normalise the GH response to GH-releasing hormone in obese subjects. Acta Endocrinologica 123:169-174, 1990.
17. Charney, DS; Deutch, AY; Krystal, JH; Southwick, SM; and Davis, M. Psychobiologic mechanisms of posttraumatic stress disorder. Arch. Gen. Psychiatry 50(4):294-305, 1993.
18. Charney, DS, and Heninger, GR. Abnormal regulation of noradrenergic function in panic disorders: Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch. Gen. Psychiatry 43:1042-1055, 1986a.
19. Charney, DS, and Heninger, GR. Serotonin function in panic disorders: The effects of intravenous tryptophan in healthy subjects and patients with panic disorder before and during alprazolam treatment. Arch. Gen. Psychiatry 43:1059-1065, 1986b.
20. Charney, DS; Heninger, GR; Sternberg, DE, et al. Adrenergic receptor sensitivity in depression: Effects of clonidine in depressed patients and healthy patients. Arch. Gen. Psychiatry 39:290-294, 1982.
21. Charney, DS; Woods, SW; Goodman, WK, et al. Serotonin function in anxiety. II: Effects of the serotonin agonist mCPP in panic disorder patients and healthy controls. Psychopharmacology (Berlin) 92:14-24, 1987.
22. Checkley, SA; Slade, AP; Schur, E, et al. Growth hormone and other responses to clonidine in patients with endogenous depression. Br. J. Psychiatry 138:51-55, 1981.
23. Chrousos, GP, and Gold, PW. The concepts of stress and stress system disorders. JAMA 267(9):1244-1252, 1992.
24. Clarke, AS; Kammerer, CM; George, KP; Kupfer, DJ; McKinney, WT; Spence, MA; and Kraemer, GW. Evidence for heritability of biogenic amine levels in the cerebrospinal fluid of rhesus monkeys. Biol. Psychiatry 38 (9):572-577, 1995.
25. Coiro, V; d'Amato, L; Borciani, E; Rossi, G; Camellini, L; Maffei, ML; Pignatti, D; and Chiodera, P. Nicotine from cigarette smoking enhances clonidine-induced increase of serum growth hormone concentrations in men. Br. J. Clin. Pharmacol. 18:802-805, 1984.
26. Coplan, JD; Andrews, MW; Rosenblum, LA; Owens, MJ; Gorman, JM; and Nemeroff, CB. Increased cerebrospinal fluid CRF concentrations in adult non-human primates previously exposed to adverse experiences as infants. Proc. Natl. Acad. Sci. USA 93(4):1619-1623, 1996.
27. Coplan, JD; Goetz, R; Klein, DF; Papp, LA; Fyer, A; Liebowitz, MR; Davies, SO; and Gorman, JM. Plasma cortisol concentrations preceding lactate-induced panic: Psychological, biochemical and physiological correlates. Arch. Gen. Psychiatry (in press a).
28. Coplan, JD; Papp, LA; Martinez, J; Rosenblum, LA; Cooper, T; Liebowitz, MR; and Gorman, JM. Persistence of blunted human growth hormone response to clonidine in panic disorder following fluoxetine treatment. Am. J. Psychiatry 619-622, 1995a.
29. Coplan, JD; Papp, LA; Pine, DS; Martinez, JM; Cooper, TB; Rosenblum, L; Klein, DF; and Gorman, J. Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorders. Arch. Gen. Psychiatry (in press b).
30. Coplan, JD; Pine, D; Papp, LA; Rosenblum, LA; Cooper, T; and Gorman, JM. Noradrenergic/HPA axis uncoupling in panic disorder. Neuropsychopharmacology 13:65-73, 1995b.
31. Coplan, JD; Rosenblum, LA; and Gorman, JM. Primate models of anxiety: Longitudinal perspectives. Psychiatr. Clin. North Am. 18(4):727-743, 1995c.
32. Corn, T; Thompson, C; and Checkley, SA. Effects of desipramine treatment upon central adrenoceptor function in normal subjects. Br. J. Psychiatry 145:139-145, 1984.
33. Coryell, W; Noyes, R, Jr; and Schlechte, J. The significance of HPA axis disturbance in panic disorder. Biol. Psychiatry 25:989-1002, 1989.
34. Darnell, A; Bremner, JD; Licinio, J; Krystal, J; Nemeroff, CB; Owens, M; Erdos, J; and Charney, DS. CSF levels of corticotropin releasing factor in chronic post-traumatic stress disorder. Soc. Neurosci. Abstr. (24th Annual Meeting) Part 1; 15.4, 1994. p. 17.
35. Davidson, RJ. Prefrontal and amygdala contributions to affect, affective style and affective disorders: EEG, PET and FMRI data (Abstract). 34th Annual Meeting of the American College of Neuropsychopharmacology, Scientific Abstracts, 1995. p. 17.
36. Dolan, RJ, and Calloway, SP. The human growth hormone response to clonidine: Relationship to clinical and neuroendocrine profile in depression. Am. J. Psychiatry 143(6):772-774, 1986.
37. Ernsberger, P; Giuliano, R; Willette, Granata, AR; and Reis, DJ. Hyportensive action of clonidine analogues correlates with binding affinity at imidazole and not alpha-2 adrenergic receptors in the rostral ventrolateral medulla. J. Hypertension 6(Suppl.):s554-s557, 1988.
38. Fossey, MD; Lydiard, RB; Ballenger, JC; Laraia, MT; Bissette, G; and Nemeroff, CB. Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biol. Psychiatry 39:703-707, 1996.
39. Frantz, AG, and Rabkin, MT. Effects of estrogen and sex differences on secretion of human growth hormone. J. Clin. Endocrinol. Metab. 25:1470-1480, 1965.
40. Gabr, RW; Birkle, DL; and Azzaro, AJ. Stimulation of the amygdala by glutamate facilitates corticotropin-releasing factor release from the median eminence and activation of the hypothalamic-pituitary-adrenal axis in stressed rats. Neuroendocrinology 62 (4):333-339, 1995.
41. Hamik, A, and Peroutka, SJ. 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol. Psychiatry 25:569-575, 1989.
42. Higley, JD; Thompson, WW; Champoux, M; Goldman, D; Hasert, MF; Kraemer, GW; Scanlan, JM; Suomi, SJ; and Linnoila, M. Paternal and maternal genetic and environmental contributions to cerebrospinal fluid monoamine metabolites in rhesus monkeys (Macaca mulatta). Arch. Gen. Psychiatry 50(8):615-623, 1993.
43. Hoehe, M; Valido, G; and Matussek, N. Growth hormone, noradrenaline, blood pressure, and cortisol responses to clonidine in healthy male volunteers: Dose-response relations and reproducibility. Psychoneuroendocrinology 13:409-418, 1988.
44. Hollander, E; DeCaria, C; Cooper, T, et al. Neuroendocrine function in obsessive-compulsive disorders: Behavioral and neuroendocrine responses to clonidine and comparison to healthy controls. Psychiatry Res. 37(2):161-177, 1991.
45. Holsboer, F. Neuroendocrinology of mood disorders. In: Bloom, FE, and Kupfer, DJ, eds. Neuropsychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1994. pp. 957-970.
46. Hunt, GE; O'Sullivan, BT; Johnson, GFS, et al. Effects of oral clonidine on growth hormone response. Psychoneuroendocrinology 11:(3)317-325, 1986.
47. Kahn, RS; Wetzler, S; Van Praag, HM, et al. Indication of serotonergic supersensitivity in panic disorder. Psychiatry Res. 25:101-104, 1988.
48. Kalin, NH; Shelton, SE; Barksdale, CM; and Brownfield, MS. A diurnal rhythm in cerebrospinal fluid corticotrophin-releasing hormone different from the rhythm of pituitary-adrenal activity. Brain Res. 24;426(2):385-391, 1987.
49. Kling, MA; Rubinow, DR; Doran, AR; Roy, A; Davis, CL; Calabrese, JR; Nieman, LK; Post, RM; Chrousos, GP; and Gold, PW. Cerebrospinal fluid immunoreactive somatostatin concentrations in patients with Cushing's disease and major depression: Relationship to indices of corticotropin-releasing hormone and cortisol secretion. Neuroendocrinology 57(1):79-88, 1993.
50. LeDoux, JE; Iwata, J; Cicchetti, P; and Reis, DJ. Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear. J. Neurosci. 8:2517-2529, 1988.
51. Mason, JW; Gillier, EL; Kosten, TR; and Harkness, L. Elevation of urinary/cortisol ratio in posttraumatic stress disorder. J. Nerv. Ment. Dis. 176 (8):498-502, 1988.
52. Matussek, N; Ackenheil, M; Hippius, H, et al. Effect of clonidine on growth hormone release in psychiatric patients and controls. Psychiatry Res. 2:25-36, 1980.
53. Middleton, HC. An enhanced hypotensive response to clonidine can still be found in panic patients despite psychological treatment. J. Anxiety Disord. 4:213-219, 1990.
54. Morgane, JP, and Jacobs, MS. Raphe projections to the locus ceruleus in the rat. Brain Res. Bull. 4:519-534, 1979.
55. Muller, E. Neural control of somatotropic function. Physiol. Rev. 67:692-1053, 1987.
56. Nemeroff, CB. New vistas in neuropeptide research in neuropsychiatry. Focus on corticotropin-releasing factor. Neuropsychopharmacology 6(2):69-75, 1992.
57. Nutt, DJ. Altered central alpha-2 sensitivity in panic disorder. Arch. Gen. Psychiatry 46:165-169, 1989.
58. Nutt, DJ, and Glue, D. Alpha-2-adrenoceptor function in alcoholics. Adv. Alcohol. Subst. Abuse 7:43-46, 1988a.
59. Nutt, DJ, and Glue, D. Aspects of alpha-2-adrenoceptor function in normal volunteers. Human Psychopharmacol. 3:235-245, 1988b.
60. O'Flynn, K; O'Keane, V; Lucey, JV; and Dinan, TG. Effect of fluoxetine on noradrenergic mediated growth hormone release: A double-blind placebo-controlled study. Biol. Psychiatry 30(4):377-382, 1991.
61. Pine, DS; Cohen, P; and Brook, J. Emotional problems during youth as predictors of stature during early adulthood: Results from a prospective epidemiologic study. Pediatrics 97(6 Pt 1):856-863, 1996.
62. Pine, DS; Coplan, JD; Papp, LA; Moreau, D; Tancer, M; Dummit, ES; Shaffer, D; Gorman, JM; and Klein, DF. Noradrenergic function in youth and adults with anxiety disorders (Abstract). Scientific Proceedings of the 42nd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, 1995.
63. Plotsky, PM; Owens, MJ; and Nemeroff, CB. In: Bloom, FE, and Kupfer, DJ, eds. Neuropsychopharmacology: The Fourth Generation of Progress. New York: Raven Press, 1995. pp. 971-981.
64. Puig-Antich, J. Affective disorders in children and adolescents: Diagnostic validity and psychobiology. In: Meltzer, HY, ed. Psychopharmocology: The Third Generation of Progress. New York: Raven Press, 1987. pp. 843-860.
65. Rapaport, MH; Risch, SC; Gillin, JC, et al. Blunted growth hormone response to peripheral infusion of human growth hormone-releasing factor in patients with panic disorder. Am. J. Psychiatry 146(1):92-95, 1989.
66. Redmond, DE. Alterations in the function of the nucleus locus ceruleus: A possible model for studies of anxiety. In: Hanin, I, and Usdin, E, eds. Animal Models in Psychiatry and Neurology. New York: Pergamon Press, 1977.
67. Reul, JM; Labeur, MS; Grigoriadis, DE; De Souza, EB; and Holsboer, F. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide. Neuroendocrinology 60(5):509-519, 1994.
68. Rosenblum, LA; Coplan, JD; Friedman, S; Bassoff, TB; and Gorman, JM. Adverse early experiences affects noradrenergic and serotonergic functioning in adult primates. Biol. Psychiatry 35:221-227, 1994.
69. Schittecatte, M; Ansseau, M; Charles, G; Machowski, R; Papart, P; Pichot, W; and Wilmotte, J. Growth hormone response to clonidine in male patients with panic disorder untreated by antidepressants. Psychol. Med. 22:1059-1062, 1992.
70. Schittecatte, M; Charles, G; Depauw, Y, et al. Growth hormone response to clonidine in panic disorder patients. Psychiatry Res. 23:147-151, 1987.
71. Schulz, DW; Chen, YL; and Heym, J. Non-peptide CRF receptor antagonists (Abstract). 34th Annual Meeting of the American College of Neuropsychopharmacology, Scientific Abstracts, 1995. p. 36.
72. Schwarz, S, and Pohl, P. Steroid hormones and steroid hormone binding globulins in cerebrospinal fluid studied in individual with intact and with disturbed blood-cerebrospinal fluid barrier. Neuroendocrinology 55(2):174-182, 1992.
73. Siever, LJ; Trestman, RL; Coccaro, EF, et al. The growth hormone response to clonidine in acute and remitted depressed male patients. Neuropsychopharmocology 6(3):165-177, 1992.
74. Siever, LJ; Uhde, TW; Silberman, EK; Jimerson, DC; Aloi, JA; Post, RM; and Murphy, DL. Growth hormone response to clonidine as a probe of noradrenergic receptor responsiveness in affective disorder patients and controls. Psychiatry Res. 6:171-183, 1982.
75. Siever, LJ; Uhde, TW; Jimerson, DC; Post, RM; Lake, CR; Murphy, DL. Plasma cortisol responses to clonidine in depressed patients and controls. Evidence for a possible alteration in noradrenergic, neuroendocrine relationships. Arch. Gen, Psychiatry 41 (1):63-68, 1984.
76. Smals, AEM; Pieters, GFFM; Smals, AGH, et al. Sex differences in human growth hormone response to intravenous human pancreatic GH-releasing hormone administration in young adults. J. Clin. Endocrinol. Metab. 62:336-341, 1986.
77. Southwick, SM; Bremner, D; Krystal, JH; Charney, DS. Psychobiologic research in post-traumatic stress disorder. Psychiatr. Clin. North Am. 17(2):251-264, 1994.
78. Spencer, GS; Dobbie, P; and Bass, JJ. Neuroendocrine regulation of growth hormone secretion in sheep. III. Serotoninergic systems. Domestic Animal Endocrinology 8(3):383-391, 1991.
79. Stein, BM, and Uhde, TW. Cortisol response to clonidine in panic disorder: Comparison with depressed patients and normal controls. Biol. Psychiatry 24:322-330, 1988.
80. Tancer, ME; Stein, MB; Black, B; and Uhde, TW. Blunted growth hormone responses to growth hormone releasing factor and to clonidine in panic disorder. Am. J. Psychiatry 150:336-337, 1993a.
81. Tancer, ME; Stein, MB; and Uhde, TW. Growth hormone response to intravenous clonidine in social phobia: Comparison to patients with panic disorder and healthy volunteers. Biol. Psychiatry 34(9):591-595, 1993b.
82. Tao, R, and Hjorth, S. Alpha-2 adrenoceptor modulation of rat ventral hippocampal 5-hydroxytryptamine release in vivo. Naunyn-Schmiedeberg's Arch. Pharmacol. 345:137-143, 1992.
83. Trestman, RL; Yehuda, R; Coccaro, E; Horvath, T; Knott, P; Gabriel, S; and Siever, LJ. Diurnal neuroendocrine and autonomic function in acute and remitted depressed males. Biol. Psychiatry 37:448-456, 1995.
84. Tulandi, T; Lal, S; and Guyda, H. Effect of estrogen on the growth hormone response to the alpha-adrenergic agonist clonidine in women in menopausal flushing. J. Clin. Endocrinol. Metab. 65:6-10, 1987.
85. Uhde, TW; Stein, MB; Vittone, BJ, et al. Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder. Arch. Gen. Psychiatry 46:170-177, 1989.
86. Uhde, TW; Tancer, ME; Rubinow, DR, et al. Evidence for hypothalamo-growth hormone dysfunction in panic disorder: Profile of growth hormone responses to clonidine, yohimbine, caffeine, glucose, GRF, and TRH in panic disorder patients versus healthy volunteers. Neuropsychopharmacology 6(2):101-118, 1992.
87. Valacavi, R; Dieguz, C; Page, M; Zini, M; Casoli, P; Portioli, I; and Scanlon, M. Alpha-2 adrenergic pathways release growth hormone via a non-GRF dependent mechanism in normal human subjects. Clin. Endocrinol. 29:309-316, 1988.
88. Vecsei, L, and Widerlov, E. Brain and CSF somatatostatin concentrations in patients with psychiatric or neurological illness. Acta Psychiatr. Scand. 78:656-667, 1988.
89. Vella, V; Tomkins, A; Borhesi, A; Migliori, GB; and Oryem, VY. Determinants of stunting and recovery from stunting in northwest Uganda. Intl. J. Epidemiol. 23(4):782-786, 1994.
90. Von Neumann, J; Kent, RH; Bellinson, HR; and Hart, BI. The mean square successive difference. Ann. Math Statistics 12(153):442-451, 1941.
91. Weissman, MW. Epidemiology of panic disorder and agoraphobia. In: Ballenger, JC. Clinical Aspects of Panic Disorder. New York: Wiley-Liss, 1990.
92. Yehuda, R; Boisoneau, D; Lowy, MT; and Giller, EL, Jr. Dose-response changes in plasma cortisol and lymphocyte glucocorticoid receptors following dexamethasone administration in combat veterans with and without posttraumatic disorder. Arch. Gen. Psychiatry 52(7):583-593, 1995.
93. Zemishlaney, Z; McQueeney, R; Gabriel, SM; and Davidson, M. Neuroendocrine and monoaminergic responses to acute administration of alprazolam in normal subjects. Neuropsychobiology 23:124-128, 1990.